secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001683168-22-008141
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals prices $6.0M public offering of shares and warrants at $3.175/unit
--------------------------------------------------------------------------------

- Gross proceeds ~$6.0M from sale of 1,889,764 units (share or pre-funded warrant + common warrant) at $3.175/unit.
- Common warrants exercisable at $3.03 per share, expire 5 years from issuance; pre-funded warrants exercisable at $0.001 per share.
- Existing warrants amended: exercise price reduced from $66/$24.60 to $3.03, expiration extended to 5 years after closing.
- Offering expected to close Dec 5, 2022; net proceeds for ongoing clinical trial, R&D, and working capital.
- H.C. Wainwright leads placement; Brookline Capital Markets co-placement; cash fee 7% of gross, plus placement agent warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316822008141/0001683168-22-008141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316822008141/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-008141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer